Liver Disease Clinical Trials

Showing 241-260 of 1,279 trials

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

NCT06449339

The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria. The main question it aims to answer is: Does carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment. Researchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality. Participants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.

Portal HypertensionHepatic DecompensationAdvanced Chronic Liver Disease

Chinese University of Hong Kong474 participantsStarted Jul 2024

Hong Kong, Hong Kong

COMPLETEDNA

Liver Health and Metabolic Function in People With Obesity

NCT03701828

This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.

Non-Alcoholic Fatty Liver Disease

Washington University School of Medicine23 participantsStarted Feb 2019

St Louis, Missouri, United States

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Liver Health and Metabolic Function in People With Obesity

Related Searches

Study of microRNAs in a Decompensated Cirrhosis

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk

Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients

FMT in Cirrhosis and Hepatic Encephalopathy

Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

Reversal of Lipid-Induced Insulin Resistance

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease